Clinical trials: Endocrine Tumor
Gastrinoma, Glucagonoma
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00131911
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer
BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment
Background: The new drug BMN 673 (talazoparib) has been shown to fight tumor cells in animals and some people. It is a poly (ADP-ribose) polymerase (PARP) inhibitor.
- Trial name
- NCT02326844
- Testing
- BMN 673 (talazoparib)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Advanced or Metastatic Solid Tumors, Ovarian Cancer
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer
- Trial name
- NCT04408599
- Testing
- NC410
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- NextCure, Inc.
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase II trial studies how well paclitaxel when given together with or without pazopanib hydrochloride works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer that is…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01468909
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pazopanib Hydrochloride
- Where
- 142 sites in United States
- Volunteers
- 106 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This is a Phase 3, open-label study to evaluate the objective response rate (ORR), in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with relacorilant in combination with nab-paclitaxel, according to…
- Trial name
- RELIANT (NCT04329949)
- Testing
- Relacorilant, 100 mg and 25 mg, Nab-paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 43 people
- Sponsor
- Corcept Therapeutics
Osteoarthritis, Rheumatoid Arthritis
Reciprocating Medical Devices - a Study of a New Safety Device
The study design is a randomized study to directly compare the performance and the outcome of syringe and needle procedures with a standard syringe or the new reciprocating procedure device (RDP), which is a type of safety…
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Trauma, Thyroid Nodule
- Trial name
- RPD (NCT00651625)
- Testing
- Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001, conventional syringe - BD Ref 309604
- Where
- United States
- Volunteers
- 437 people
- Sponsor
- University of New Mexico
Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
This phase II trial studies how well iodine I-131 works with or without selumetinib in treating patients with thyroid cancer that has returned (recurrent) or has spread from where it started to other places in the body…
- Conditions
- Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
- Trial name
- NCT02393690
- Testing
- Iodine I-131, Selumetinib
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- Academic and Community Cancer Research United
Peritoneal Surface Malignancy, Postoperative Adhesion
SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive Surgery
This dual-centre, randomized controlled trial evaluates the safety and efficacy of high-purity Type-I collagen-based biomaterial, as a peritoneal substitute following peritonectomy in patients undergoing cytoreductive surgery…
- Conditions
- Peritoneal Surface Malignancy, Postoperative Adhesion, Bowel Obstruction, Wound Complications
- Trial name
- NCT07241091
- Testing
- High-Purity Type-I Collagen Scaffold, Standard Peritonectomy Closure
- Where
- 2 sites in India
- Volunteers
- 60 people
- Sponsor
- Adichunchanagiri Institute of Medical Sciences, B G Nagara
Locally Advanced Pancreatic Adenocarcinoma
Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
Open-label, dose-escalating, Phase IIa trial of NanoPac® to treat subjects with locally advanced pancreatic adenocarcinoma via direct intratumoral injection.
- Trial name
- NCT03077685
- Testing
- NanoPac®
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- NanOlogy, LLC
Malignant Ascites
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
The purpose of this study is to determine whether the investigational drug catumaxomab is a safe and effective treatment for recurrent symptomatic malignant ascites.
- Trial name
- NCT00326885
- Testing
- catumaxomab
- Where
- 18 sites in United States
- Volunteers
- 32 people
- Sponsor
- Neovii Biotech
Pancreatic Ductal Adenocarcinoma
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Patients with metastatic, locally advanced, or unresectable pancreatic ductal carcinomas (PDA) who have failed prior chemotherapy with gemcitabine regimens have an extremely poor prognosis with progression-free survival of around…
- Trial name
- NCT01580397
- Testing
- INNO-206
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
Pancreatic Cancer
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
The purpose of this study is to help us learn more about how to lower the patient's risk of the most common complications after their pancreas operation.
- Trial name
- NCT00994110
- Testing
- Pasireotide (SOM230)
- Where
- United States
- Volunteers
- 439 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor…
- Trial name
- NCT00305760
- Testing
- Cetuximab, Pancreatic tumor vaccine, Cyclophosphamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Polycystic Ovarian Syndrome, Vitamin D Deficiency
Health Benefits of Vitamin D and Calcium in Women With PCOS (Polycystic Ovarian Syndrome)
The investigators conducted a prospective un-blinded pilot study of Vitamin D plus Calcium (Ca) supplementation in overweight (BMI > 27) premenopausal women diagnosed with Polycystic Ovarian Syndrome (PCOS), as defined by the…
- Trial name
- NCT00743574
- Testing
- Vitamin D2 (Ergocalciferol), Medroxyprogesterone (Provera), Vitamin D3 (Cholecalciferol)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Yale University
Metastatic Pancreatic Cancer, Colorectal Cancer
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors
The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic…
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Trial name
- NCT03261947
- Testing
- TAK-931
- Where
- 10 sites in United States, Japan
- Volunteers
- 101 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients with stage III or stage IV ovarian epithelial…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT00262847
- Testing
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis
- Where
- 632 sites in United States, Canada and 2 more
- Volunteers
- 1,873 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian, Breast
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and…
- Conditions
- Ovarian, Breast, SCLC, Gastric Cancers
- Trial name
- MEDIOLA (NCT02734004)
- Testing
- Olaparib, MEDI4736, Bevacizumab
- Where
- 47 sites in United States, France and 5 more
- Volunteers
- 264 people
- Sponsor
- AstraZeneca
Polycystic Ovary Syndrome
Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
The classic description of polycystic ovary syndrome (PCOS) is that it is a disorder characterized by menstrual irregularity, chronic anovulation, androgen excess, and abnormal gonadotropin secretion.
- Trial name
- BEYAZ-PCOS (NCT01360996)
- Testing
- 3 mg DRSP/20 μg EE
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Woman's
Type 2 Diabetes
Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Background: Pioglitazone has been shown to have potent anti-inflammatory as well anti-atherosclerotic effects. However, the mechanisms by which pioglitazone exerts these effects are not clear.
- Trial name
- PIO-TACE (NCT01223196)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.